

Agata Mulak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9421224/publications.pdf>

Version: 2024-02-01

42
papers

3,222
citations

361413

20
h-index

276875

41
g-index

54
all docs

54
docs citations

54
times ranked

4147
citing authors

#	ARTICLE	IF	CITATIONS
1	Small intestinal bacterial overgrowth in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 75-83.	2.8	7
2	Microbiota medicine: towards clinical revolution. <i>Journal of Translational Medicine</i> , 2022, 20, 111.	4.4	87
3	Impact of Primary and Secondary Bile Acids on <i>Clostridioides difficile</i> Infection. <i>Polish Journal of Microbiology</i> , 2022, 71, 11-18.	1.7	5
4	Sexual Dimorphism in the Gut Microbiome: Microgenderome or Microsexome?. <i>Journal of Neurogastroenterology and Motility</i> , 2022, 28, 332-333.	2.4	6
5	Physiological and pathophysiological role of endocrine fibroblast growth factors. <i>Postepy Higieny i Medycyny Doswiadczalnej</i> , 2022, 76, 39-53.	0.1	0
6	Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease. <i>Advances in Alzheimer's Disease</i> , 2022, , .	0.2	0
7	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	1.3	913
8	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021, 9, 307-331.	3.8	62
9	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. <i>United European Gastroenterology Journal</i> , 2021, 9, 287-306.	3.8	60
10	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14237.	3.0	25
11	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	3.0	21
12	Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 461-477.	2.6	36
13	The impact of probiotics on interactions within the microbiota-gut-lung triad in COVID-19. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 577-578.	2.8	5
14	Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 733070.	2.0	2
15	An overview of the neuroendocrine system in Parkinson's disease: what is the impact on diagnosis and treatment?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 127-135.	2.8	7
16	An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-6.	1.5	3
17	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13930.	3.0	15
18	Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 247-250.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 992.	2.8	58
20	Brain-Gut-Microbiota Axis in Alzheimer's Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 48-60.	2.4	496
21	A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 398-401.	3.9	35
22	Guidelines on the management of irritable bowel syndrome. <i>Przeegląd Gastroenterologiczny</i> , 2018, 13, 259-288.	0.7	24
23	Increased Level of Fibroblast Growth Factor 19 in Patients with Ulcerative Colitis in Remission. <i>Gastroenterology</i> , 2017, 152, S969-S970.	1.3	1
24	Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	1.5	13
25	Diagnostic challenges in celiac disease. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 729-737.	1.4	22
26	Pancreatic duct stones – a report of 16 cases. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 609-613.	1.4	5
27	The HLA-DQ*1 insertion is a strong achalasia risk factor and displays a geospatial north-south gradient among Europeans. <i>European Journal of Human Genetics</i> , 2016, 24, 1228-1231.	2.8	21
28	Lessons learned – resolving the enigma of genetic factors in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 77-87.	17.8	76
29	Brain-gut-microbiota axis in Parkinson's disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 10609.	3.3	438
30	Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice. <i>Peptides</i> , 2015, 63, 71-80.	2.4	9
31	Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 163.	3.3	148
32	Sex hormones in the modulation of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2014, 20, 2433.	3.3	188
33	The Lifetime Prevalence of Anxiety Disorders Among Patients with Irritable Bowel Syndrome. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 987-992.	1.4	17
34	Association of Polymorphisms in 5-HT _{2A} and 5-HT _{2C} Receptors Genes With Depressive and Anxiety Disorders in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2013, 144, S-725.	1.3	2
35	Psychological Stress Induces Visceral Analgesic or Hyperalgesic Response in Rodents: A Role of Preconditions. <i>Frontiers of Gastrointestinal Research</i> , 2012, 30, 106-114.	0.1	7
36	Stress and visceral pain: From animal models to clinical therapies. <i>Experimental Neurology</i> , 2012, 233, 49-67.	4.1	175

#	ARTICLE	IF	CITATIONS
37	Stress-Related Alterations of Visceral Sensation: Animal Models for Irritable Bowel Syndrome Study. <i>Journal of Neurogastroenterology and Motility</i> , 2011, 17, 213-234.	2.4	70
38	Anorectal Function and Visceral Hypersensitivity in Celiac Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e249-e252.	2.2	7
39	Anorectal function and dyssynergic defecation in different subgroups of patients with irritable bowel syndrome. <i>International Journal of Colorectal Disease</i> , 2010, 25, 1011-1016.	2.2	19
40	Sex difference in irritable bowel syndrome: do gonadal hormones play a role?. <i>Gastroenterologia Polska</i> , 2010, 17, 89-97.	1.0	22
41	Effect of 5-HT ₁ agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 1591.	3.3	6
42	Irritable bowel syndrome: a model of the brain-gut interactions. <i>Medical Science Monitor</i> , 2004, 10, RA55-62.	1.1	96